Skip to main content
Journal of Diabetes logoLink to Journal of Diabetes
. 2021 Dec 28;14(2):121–133. doi: 10.1111/1753-0407.13244

New clusters of serum electrolytes aid in stratification of diabetes and metabolic risk

聚类分析显示血清电解质簇有助于糖尿病及代谢异常风险人群分层

Yanan Hou 1,2, Jiali Xiang 1,2, Huajie Dai 1,2, Tiange Wang 1,2, Mian Li 1,2, Hong Lin 1,2, Shuangyuan Wang 1,2, Yu Xu 1,2, Jieli Lu 1,2, Yuhong Chen 1,2, Weiqing Wang 1,2, Guang Ning 1,2, Zhiyun Zhao 1,2, Yufang Bi 1,2, Min Xu 1,2,
PMCID: PMC9060051  PMID: 34963041

Abstract

Background

Serum electrolytes were found to associate with type 2 diabetes. Our study aimed to stratify nondiabetes by clusters based on multiple serum electrolytes and evaluate their associations with risk of developing diabetes and longitudinal changes in glucose and lipid metabolic traits.

Methods

We performed a data‐driven cluster analysis in 4937 nondiabetes individuals aged ≥40 years at baseline from a cohort follow‐up for an average of 4.4 years. Cluster analysis was based on seven commonly measured serum electrolytes (iron, chlorine, magnesium, sodium, potassium, calcium, and phosphorus) by using the k‐means method.

Results

A total of 4937 nondiabetes individuals were classified into three distinct clusters, with 1635 (33.1%) assigned to Cluster A, 1490 (30.2%) to Cluster B, and 1812 (36.7%) to Cluster C. Individuals in Cluster A had higher serum chlorine, were older, and more were women. Individuals in Cluster B had higher serum iron and body mass index (BMI). Individuals in Cluster C had higher serum phosphorus, were younger, and had lower BMI. Cluster B had 1.41‐fold higher risk of developing diabetes and Cluster C’s risk was 1.33‐fold higher compared with Cluster A. Over an average follow‐up of 4.4 years, Cluster A showed a moderate and stable BMI, Cluster B showed an accelerated deterioration in glucose metabolism, and Cluster C showed the most sharply increased serum low‐density lipoprotein cholesterol level.

Conclusions

Clusters based on seven common serum electrolytes differed in diabetes risk and progression of glucose and lipid metabolic traits. Serum electrolytes clusters could provide a powerful tool to differentiate individuals into different risk stratification for developing type 2 diabetes.

Keywords: cluster analysis, metabolic risk, risk stratification, serum electrolytes, type 2 diabetes


Highlights

  • Three identified clusters based on seven commonly measured serum electrolytes had different metabolic profiles, associated with distinct risk of developing diabetes and progression of glucose and lipid metabolic traits.

  • Individuals in Cluster A were older, more were women, and had “normal” to low risk for diabetes. Individuals in Cluster B were at a high risk and with significant deterioration in glucose metabolism. Individuals in Cluster C were younger, at a moderate risk and with more deleterious lipids metabolism.

  • This provides a convenient method of risk stratification for nondiabetes.

graphic file with name JDB-14-121-g001.jpg

1. INTRODUCTION

Diabetes has become a big epidemic with 463 million adults affected globally in 2019 and the figure is projected to reach 700 million by 2045. 1 Of note, China now is facing the world’s largest diabetes epidemic in that more than 12.8% of adults are estimated to have diabetes and more than 35.2% to have prediabetes in 2018. 2 Diabetes, together with its related cardiometabolic risk profiles, imposed a huge burden on cardiovascular diseases, mortality, and health care expenditure. 3 , 4 Early identification and stratification for risk of developing diabetes was crucial for better management and prevention of diabetes and its related cardiometabolic disorders.

Diabetes is a disease with high heterogeneity in clinical presentation, disease progression, and etiopathogenesis, which makes it difficult to implement individualized treatment, achieve adequate glucose control, and predict prognosis in affected individuals. These issues might be attributed to the fact that diabetes diagnosis is oversimplified via the evaluation of plasma glucose solely. 5 Adopting cluster analyses to refine the classification of diabetes beyond the simple use of plasma glucose is a powerful tool to detect diabetes subphenotypes with specific patterns of complications. 5 Using demographic and clinical variables, several recent studies successfully provided a refined classification of diabetes, which aids in characterizing and exploiting diabetes heterogeneity, identifying risk of complications at diagnosis, and optimizing precision medicine according to subphenotypes of diabetes. 6 , 7 , 8 , 9 , 10 , 11 Indeed, metabolic abnormalities characterizing prediabetes already exist 6 years before diabetes onset. 12 The macrovascular and microvascular complications of diabetes also need preventive care before diabetes onset. However, studies on risk evaluation and stratification of developing diabetes in the nondiabetes East Asian population are sparse. 13

A very recent study adopted fat composition, insulin secretion, insulin sensitivity, and genetic risk to classify individuals at elevated risk for diabetes. They identified six distinctive subphenotypes with different metabolic risk. The study indicated adopting multivariables to recapitulate subphenotypes for individuals at elevated risk for diabetes would aid in disentangling metabolic heterogeneity, assessing diabetes and complication risks, and benefiting precision medicine. 13

Serum electrolytes, including iron, chlorine, magnesium, sodium, potassium, calcium, and phosphorus, are important cofactors for multiple enzymes and play a pivotal role in many key biological and physiological processes, including glucose metabolism. 14 , 15 , 16 The excess or deficiency of these electrolytes was found to be linked to deleterious metabolism status. 14 Many studies have reported single serum electrolyte level, such as magnesium, calcium, and ferritin, was associated with risk of type 2 diabetes and related metabolic abnormalities. 17 , 18 , 19 , 20 The Rotterdam study with a median follow‐up of 6.7 years 17 reported that each 0.1 mmol/L decrease in serum magnesium was associated with 1.12‐fold greater prediabetes risk and 1.18‐fold greater diabetes risk. In another two prospective cohorts, 18 , 20 researchers reported that a high level of baseline serum calcium was associated with an increased risk of developing type 2 diabetes. It indicated that serum electrolytes were a feasible clinical index used for predicting diabetes and prediabetes. However, few studies have systematically and comprehensively assessed the effects of serum electrolytes distribution pattern rather than specific concentration of serum electrolytes on the risk of incident diabetes.

Our study aimed to, first, create clusters in individuals who were nondiabetic at baseline based on seven systematically measured and clinical‐conveniently available serum electrolytes by using cluster analysis; and second, evaluate the associations of these clusters with risk of developing diabetes and longitudinal change patterns of metabolic traits in an average 4.4 years follow‐up Chinese adults. The current study will provide a refined classification of nondiabetes into different stratifications of developing type 2 diabetes and progression of metabolic traits.

2. METHODS

2.1. Study population

The prospective study is a community‐based survey on type 2 diabetes and related cardiometabolic diseases conducted in Jiading district, Shanghai, China. 21 , 22 In phase I (March–August 2010), 10 375 of 10 569 registered permanent residents aged 40 years or older underwent the baseline examination. Individuals with cardiovascular diseases (n = 306) or type 2 diabetes (n = 1755) or missing data on serum electrolytes, type 2 diabetes, or cardiovascular diseases (n = 329) at baseline were excluded. In phase II (August 2014‐May 2015), 7965 nondiabetes individuals were enrolled to complete a follow‐up survey. Of these, 153 individuals died during follow‐up period, and 2788 individuals failed to attend the onsite follow‐up visit. Seventy eight individuals were missing data on diabetes status at follow‐up visit, and four individuals with extreme outliers (>2 SD from the mean of serum phosphorus level) were excluded. Finally, 4937 nondiabetes individuals were included in the current analysis. The detailed selection process of study participants is shown in Figure 1.

FIGURE 1.

FIGURE 1

Flow chart of the present study

The study protocol was approved by the Committee on Human Research at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. All participants provided written informed consent.

2.2. Biochemical measurements

Blood samples were collected at phase I and II after ≥10 h overnight fasting. Each individual underwent a simplified 75 g oral glucose tolerance test (OGTT). Plasma glucose (0 and 2 h) and serum insulin (0 and 2 h) was determined using glucose oxidize method (Modular P800; Roche, Basel, Switzerland) and chemiluminescence method (Modular E170; Roche, Basel, Switzerland), respectively. Serum electrolytes (iron, chlorine, magnesium, sodium, potassium, calcium, and phosphorus) were determined using chemiluminescence method (Modular E170; Roche, Basel, Switzerland). Glycated hemoglobin A1c (HbA1c) and serum creatinine were determined using high‐performance liquid chromatography (VARIANT II Hemoglobin Testing System, Bio‐Rad Laboratories) and picric acid method (clinical chemistry diagnostic system C16 000, Abbott Laboratories, Otawara‐shi, Japan), respectively. Serum apolipoprotein A (APOA), apolipoprotein B (APOB), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), triglycerides (TG), total cholesterol (TC), aspartate aminotransferase (AST), γ‐ glutamyl transpeptidase (GGT), and alanine aminotransferase (ALT) were determined using chemiluminescence method (Modular E170; Roche, Basel, Switzerland).

2.3. Ascertainment of incident diabetes

Incident diabetes cases were defined as (a) fasting plasma glucose ≥7.0 mmol/L; (b) 2 h‐OGTT plasma glucose ≥11.1 mmol/L; (c) individuals were receiving antidiabetic medications; and (d) self‐reported diagnosed diabetes. The homeostasis model assessment of insulin resistance (HOMA‐IR) was calculated using the formula fasting plasma glucose (mmol/L) × serum fasting insulin (mIU/L) /22.5. The homeostasis model assessment of function of β cells (HOMA‐β) was calculated using the formula: 20 × fasting serum insulin (mIU/L)/[fasting plasma glucose (mmol/L)‐3.5].

2.4. Covariates

Information about demographics, lifestyles, diseases history, and medication use were collected through a standard questionnaire. Individuals who consumed alcohol or smoked cigarettes regularly in the past 6 months were regarded as current drinking or smoking. Physical activity was evaluated using International Physical Activity Questionnaire 23 and divided into three levels on the basis of metabolic equivalent (MET): vigorous (≥3000 MET‐min/week), moderate (600–2999 MET‐min/week), and mild (≤599 MET‐min/week). 24 , 25

Body weight, height, diastolic blood pressure (DBP), systolic blood pressure (SBP), fat‐free mass, and fat mass were measured using a standard protocol. Three seated SBP and DBP at nondominant arm were measured consecutively with 1 min intervals after 10 min of rest (OMRON Model HEM‐752 FUZZY, Omron Company, Dalian, China). These three measurements were averaged for analysis. Fat‐free mass and fat mass were evaluated on a body composition analyzer (Tanita TBF‐300, Japan) by bioelectrical impedance analysis.

2.5. Cluster analysis

Baseline fasting serum iron, chlorine, magnesium, sodium, potassium, calcium, and phosphorus were selected as model variables for cluster analysis. Cluster analysis was done on values centered to an SD of 1 and a mean value of 0. In the TwoStep clustering, we first calculated the optimal clustering value using the elbow method (R version 4.0.3) and then dose K‐means clustering (k = 3) using the k‐means runs function (runs = 100).

2.6. Statistical analysis

Baseline characteristics were described according to the three clusters. Continuous variables were presented as mean ± SD or medians (interquartile range), whereas categorical variables were presented as numbers (percentage). The multiple comparisons of baseline characteristics among clusters were conducted by Student‐Newman‐Keuls (SNK) test.

Logistic regression analysis was performed to determine the risk of developing diabetes in relation to clusters. Risk estimates were described as odds ratios (OR) and 95% confidence intervals (CIs). Model 1, adjusted for sex, age (years), body mass index (BMI) (kg/m2), family history of diabetes (yes or no); Model 2, further adjusted for current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate, or vigorous), education level (≥9 years of education or not); Model 3, further adjusted for systolic blood pressure (mmHg), diastolic blood pressure (mmHg), fasting plasma glucose (mmol/L), 2 h‐OGTT plasma glucose (mmol/L), serum creatinine (umol/L), TC (mmol/L), TG (mmol/L), HDL‐C (mmol/L), LCL‐C (mmol/L), and use of diuresis (yes or no) based on model 2. To assess the added value of serum electrolytes clusters, we included these clusters in the models of predicting diabetes. We calculated the difference (C statistic) without or with clusters, integrated discrimination improvement (IDI), and net reclassification improvement (NRI).

All statistical analyses were conducted using SAS (version 9.4, SAS Institute, Cary, NC). A two‐tailed p value < 0.05 was considered as statistical significance.

3. RESULTS

3.1. Baseline characteristics

A total of 4937 nondiabetes individuals were included in the current analysis, with an average age of 57.3 ± 8.6 years, 1721 (35%) men, and 3216 (65%) women. We used the k‐means clustering method to classify individuals into three different clusters based on the seven serum electrolytes, with the minimum sum of the squared errors. The baseline characteristics according to the three clusters were shown in Figures 2, 3 and Table 1. Cluster A, including 1635 (33.1%) individuals, was characterized as elder age, more women, with higher level of serum chloride, fasting and 2 h‐OGTT serum insulin and HOMA‐β, and lower level of TG, Cluster B, including 1490 (30.2%) individuals, had higher level of serum iron, magnesium, potassium, and calcium, BMI, DBP, fasting plasma glucose, TC, HDL‐C, LDL‐C, and liver enzymes (ALT, AST, and GGT), fat mass, and fat‐free mass, but lower level of fasting and 2 h‐OGTT serum insulin, HOMA‐IR, and HOMA‐β. Cluster C, including 1812 (36.7%) individuals, had higher level of serum phosphorus and HbA1c, younger age, lower level of BMI, SBP, serum creatinine and AST, and moderate level of fasting and OGTT‐2 h serum insulin, HOMA‐β, fat‐free mass, and fat mass.

FIGURE 2.

FIGURE 2

Clusters distribution and the characteristics of serum electrolytes in each cluster. (A) Proportions of the three clusters in total study participants (n = 4937) according to k‐means clustering methods. (B) Characteristics of serum electrolytes at baseline in each cluster. Data were shown as means and SDs. Green = Cluster A, red = Cluster B, and yellow  = Cluster C

FIGURE 3.

FIGURE 3

The patterns of a wide range of baseline metabolic characteristics of the participants according to the three clusters. The right bar with color gradient was presented the range of mean values of each metabolic trait. Abbreviations: APOA, apolipoprotein A; APOB, apolipoprotein B; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ‐ glutamyl transpeptidase; HbA1c, glycated hemoglobin A1c; HDL‐C, high density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment of insulin resistance; HOMA‐β, homeostasis model assessment of β cells; LDL‐C, low density lipoprotein cholesterol; OGTT, oral glucose tolerance test; TC, total cholesterol

TABLE 1.

Baseline characteristics of study participants according to the three clusters

Cluster A Cluster B Cluster C p value SNK test
n 1635 1490 1812
Age, years 58.5 ± 8.83 57.1 ± 8.35 56.3 ± 8.57 <0.0001 A, B, C
Women, n (%) 1222 (74.7) 697 (46.8) 1297 (71.6) <0.0001 A, C, B
Body mass index, kg/m2 24.9 ± 3.23 25.3 ± 3.00 24.6 ± 3.15 <0.0001 B, A, C
Systolic blood pressure, mmHg 140 ± 20.2 141 ± 18.6 138 ± 19.4 <0.0001 (B, A), C
Diastolic blood pressure, mmHg 82.3 ± 10.4 84.6 ± 10.0 82.0 ± 10.2 <0.0001 B, (A, C)
Current smoking, n (%) 220 (14.0) 454 (31.0) 266 (15.4) <0.0001 B, (C, A)
Current drinking, n (%) 108 (22.8) 226 (15.4) 140 (8.05) <0.0001 A, B, C
Physical activity, MET‐h/wk 21.0 (0–38.5) 15.0 (0–35.0) 15.0 (0–33.6) 0.20 /
≥9 years of education, n (%) 309 (18.9) 284 (19.1) 410 (22.6) 0.009 C, (A, B)
Family history of diabetes, n (%) 126 (7.72) 122 (8.20) 204 (11.3) 0.0004 C, (A, B)
Use of diuresis, n (%) 20 (1.22) 24 (1.61) 43 (2.37) 0.03 C, (A, B)
Biochemical measurements
Fasting plasma glucose, mmol/L 5.06 ± 0.54 5.17 ± 0.59 5.08 ± 0.56 <0.0001 B, (C, A)
2 h‐OGTT plasma glucose, mmol/L 6.66 ± 1.70 6.58 ± 1.81 6.66 ± 1.69 0.32 /
Fasting serum insulin, mIU/L 6.80 (5.00–9.40) 6.28 (4.10–9.00) 6.70 (4.65–9.35) <0.0001 A, C, B
2 h‐OGTT serum insulin, mIU/L 46.2 (26.8–66.5) 39.6 (22.9–63.1) 42.5 (25.6–67.4) <0.0001 A, C, B
HOMA‐IR 1.53 (1.09–2.14) 1.43 (0.92–2.13) 1.49 (1.02–2.17) 0.02 (A, C), B
HOMA‐β 91.1 (65.7–132) 77.9 (50.0–116) 88.9 (61.3–131) <0.0001 A, C, B
Serum creatinine, umol/L 60.5 ± 13.2 64.6 ± 13.2 58.9 ± 11.9 <0.0001 B, A, C
Total cholesterol, mmol/L 5.26 ± 0.96 5.46 ± 0.95 5.30 ± 1.05 <0.0001 B, (C, A)
Triglycerides, mmol/L 1.28 (0.92–1.78) 1.35 (0.99–1.90) 1.35 (0.95–1.91) 0.0001 (C, B), A
High‐density lipoprotein cholesterol, mmol/L 1.34 ± 0.31 1.37 ± 0.32 1.32 ± 0.32 <0.0001 B, (A, C)
Low‐density lipoprotein cholesterol, mmol/L 3.17 ± 0.85 3.26 ± 0.81 3.15 ± 0.86 0.0005 B, (A, C)
Serum electrolytes
Iron, umol/L 16.8 ± 4.85 22.1 ± 5.62 16.4 ± 4.99 <0.0001 B, A, C
Chlorine, mmol/L 105 ± 2.07 102 ± 2.13 102 ± 2.14 <0.0001 A, (B, C)
Magnesium, mmol/L 0.90 ± 0.07 0.94 ± 0.07 0.90 ± 0.07 <0.0001 B, (A, C)
Sodium, mmol/L 146 ± 1.41 144 ± 1.64 142 ± 1.46 <0.0001 A, B, C
Potassium, mmol/L 4.07 ± 0.35 4.46 ± 0.39 3.98 ± 0.32 <0.0001 B, A, C
Calcium, mmol/L 2.31 ± 0.10 2.34 ± 0.10 2.29 ± 0.10 <0.0001 B, A, C
Phosphorus, mmol/L 1.27 ± 0.18 1.16 ± 0.18 1.32 ± 0.19 <0.0001 C, A, B

Data are presented as means ± SD (SD), or medians (interquartile ranges) for skewed variables, or number (percentage) for categorical variables. Multiple comparisons were performed by Student‐Newman‐Keuls (SNK) test. Abbreviations: HOMA‐IR, homeostasis model assessment of insulin resistance; HOMA‐β, homeostasis model assessment of β cells; OGTT, oral glucose tolerance test; SNK test, Student‐Newman‐Keuls test. A, B, and C represent cluster A, cluster B, and cluster C, respectively. Letters within brackets indicate means in different clusters are not significantly different.

3.2. Associations of clusters by serum electrolytes with risk of incident diabetes

A total of 601 incident diabetes cases were identified over an average of follow‐up of 4.4 years, including 163 (10.0%) in Cluster A, 217 (14.6%) in Cluster B, and 221 (12.2%) in Cluster C.

Compared with Cluster A, Clusters B and C were associated with a higher risk of incident diabetes (Table 2). Cluster B was associated with 1.56‐fold (95% CI 1.25‐1.96, p = 0.0001) and Cluster C 1.37‐fold (95% CI 1.10‐1.70, p = 0.005) higher risk of incident diabetes, respectively, after adjustments for age, sex, BMI, and family history of diabetes (model 1). Further adjustments for the demographic and lifestyle factors, SBP, DBP, fasting, and 2 h‐OGTT plasm glucose, serum creatinine, HDL‐C, TG, TC, and LDL‐C, and use of diuresis (model 3), the results did not appreciably change, the ORs for Cluster B and C were 1.41 (95% CI 1.09‐1.82, p = 0.01) and 1.33 (95% CI 1.03‐1.71, p = 0.03), respectively. However, there was no significant difference between the association of the risk of incident diabetes with Cluster B and C (p > 0.05).

TABLE 2.

Risk of incident diabetes in relation to Cluster B and C, as compared with Cluster A

Cluster A Cluster B Cluster C
OR (95% CI) p value OR (95% CI) p value
n, cases/participants 163/1635 217/1490 221/1812
Model 1 Ref. 1.56 (1.25–1.96) 0.0001 1.37 (1.10–1.70) 0.005
Model 2 Ref. 1.57 (1.25–1.98) 0.0001 1.36 (1.09–1.70) 0.007
Model 3 Ref. 1.41 (1.09–1.82) 0.01 1.33 (1.03–1.71) 0.03

Data are presented as odds ratio (ORs) and 95% confidence interval (CI). Model 1, adjusted for sex, age (years), body mass index (kg/m2), family history of diabetes (yes or no); Model 2, further adjusted for current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), education level (≥9 years of education or not); Model 3, further adjusted for systolic blood pressure (mmHg), diastolic blood pressure (mmHg), fasting plasma glucose (mmol/L), 2 h‐OGTT plasma glucose (mmol/L), serum creatinine (mmol/L), total cholesterol (mmol/L), triglycerides (mmol/L), high‐density lipoprotein cholesterol (mmol/L), low‐density lipoprotein cholesterol (mmol/L), and use of diuresis (yes or no) based on model 2.

3.3. Progression of glucose and lipid metabolic traits over 4.4 years

The changes in major glucose and lipid metabolic traits over 4.4 years by clusters were shown in Figure 4. All the three clusters showed an obvious decreased level of SBP, DBP, and HOMA_β, the increased level of fasting and 2 h‐OGTT plasma glucose, fasting, and 2 h‐OGTT serum insulin, and HOMA_IR. In Cluster A, the glucose and lipid metabolic traits were characterized by a moderate and stable BMI and increased level of serum HDL‐C. Cluster B showed a sharply increased level of 2 h‐OGTT plasma glucose, a slightly decreased level of serum HDL‐C. Cluster C was shown as in between Cluster B and A, except the most sharply increased level of serum LDL‐C.

FIGURE 4.

FIGURE 4

Progression of glucose and lipid metabolic traits over 4.4 years according to the three clusters. The lines show the change trends of the glucose and lipid metabolic traits from baseline to the 4.4 years of follow‐up. Green = Cluster A, red = Cluster B, and yellow = Cluster C. The glucose and lipid metabolic traits included BMI (A), systolic blood pressure (B), diastolic blood pressure (C), fasting plasma glucose (D), 2 h‐OGTT plasma glucose (E), fasting serum insulin (F), 2 h‐OGTT serum insulin (G), HOMA‐IR (H), HOMA‐β (I), triglycerides (J), high‐density lipoprotein cholesterol (K), and low‐density lipoprotein cholesterol (L). Abbreviations: BMI, body mass index; HDL cholesterol, high density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment of insulin resistance; HOMA‐β, homeostasis model assessment of β cells; LDL cholesterol, low density lipoprotein cholesterol; OGTT, oral glucose tolerance test

3.4. Association of selected serum electrolyte with risk of incident diabetes

We evaluated the associations of each of the seven serum electrolytes with risk of incident diabetes (Table 3). Each 1‐SD increase in serum chlorine (2.8 mmol/L) was associated with 12% lower risk of incident diabetes (OR = 0.88, 95% CI 0.80‐0.97, p = 0.01) risk of incident diabetes. The corresponding results for serum magnesium (0.07 mmol/L) was 13% (OR = 0.87, 95% CI 0.80‐0.96, p = 0.005), serum potassium (0.4 mmol/L) was 12% (OR = 0.88, 95% CI 0.81‐0.97, p = 0.009), and serum solidum (2.0 mmol/L) was 11% (OR = 0.89, 95% CI 0.81‐0.98, p = 0.01). Each 1‐SD increase in serum iron (5.7 umol/L) was associated with 1.26‐fold (95% CI 1.14‐1.39, p < 0.0001) increased risk of incident diabetes. No significant association were found for calcium (0.1 mmol/L) and serum phosphorus (0.2 mmol/L) (both p ≥ 0.35). The categorical analysis showed similar results (all p for trend ≤ 0.04, except for potassium, calcium, and phosphorus).

TABLE 3.

Risk of incident diabetes in relation to selected dominant serum electrolytes in each cluster

Each 1‐SD increase Tertile 1 Tertile 2 Tertile 3
1‐SD OR (95% CI) p value OR (95% CI) OR (95% CI) p for trend
Serum chlorine
Unit, mmol/L 2.8 94–101 102–104 105–113
n, cases/participants 603/4941 246/1507 236/2040 121/1304
Model 1 0.75 (0.69–0.82) <0.0001 Ref 0.69 (0.57–0.84) 0.47 (0.37–0.60) <0.0001
Model 2 0.88 (0.80–0.97) 0.01 Ref 0.81 (0.65–1.00) 0.64 (0.50–0.83) 0.0007
Serum iron
Unit, umol/L 5.7 3.6–15.5 15.6–20.1 32.7–54.5
n, cases/participants 603/4941 173/1653 186/1631 244/1657
Model 1 1.18 (1.07–1.29) 0.0006 Ref 0.99 (0.79–1.23) 1.38 (1.11–1.73) 0.003
Model 2 1.26 (1.14–1.39) <0.0001 Ref 1.05 (0.82–1.34) 1.60 (1.25–2.05) 0.0001
Serum magnesium
Unit, mmol/L 0.07 0.63–0.87 0.88–0.93 0.94–1.56
n, cases/participants 603/4941 196/1523 195/1730 212/1688
Model 1 0.96 (0.88–1.04) 0.29 Ref 0.84 (0.68–1.05) 0.93 (0.75–1.15) 0.50
Model 2 0.87 (0.80–0.96) 0.005 Ref 0.83 (0.65‐1.05) 0.78 (0.62‐0.99) 0.04
Serum potassium
Unit, mmol/L 0.4 2.85–3.96 3.97–4.30 4.31–6.03
n, cases/participants 603/4941 200/1639 200/1666 203/1636
Model 1 0.98 (0.90–1.07) 0.67 Ref 1.02 (0.83–1.26) 1.03 (0.83–1.27) 0.82
Model 2 0.88 (0.81–0.97) 0.009 Ref 1.01 (0.80–1.28) 0.83 (0.66–1.05) 0.12
Serum sodium
Unit, mmol/L 2.0 135–142 143–145 146–155
n, cases/participants 603/4941 155/1163 305/2599 143/1179
Model 1 0.93 (0.85–1.01) 0.09 Ref 0.81 (0.66–1.01) 0.80 (0.62–1.03) 0.08
Model 2 0.89 (0.81–0.98) 0.02 Ref 0.78 (0.62–0.99) 0.69 (0.53–0.91) 0.01
Serum calcium
Unit, mmol/L 0.1 1.92–2.27 2.28–2.35 2.36–2.77
n, cases/participants 603/4941 191/1729 186/1618 226/1594
Model 1 1.11 (1.02–1.21) 0.01 Ref 1.03 (0.83–1.28) 1.31 (1.06–1.61) 0.01
Model 2 0.96 (0.87–1.05) 0.35 Ref 0.91 (0.72–1.16) 0.89 (0.70–1.13) 0.33
Serum phosphorus
Unit, mmol/L 0.2 0.72–1.15 1.16–1.34 1.35–3.06
n, cases/participants 603/4941 208/1620 196/1705 199/1616
Model 1 1.00 (0.99–1.01) 0.91 Ref 0.92 (0.74–1.14) 1.00 (0.81–1.24) 0.98
Model 2 1.00 (0.99–1.01) 0.66 Ref 0.99 (0.78–1.25) 1.03 (0.81–1.31) 0.81

Data are presented as odds ratio (ORs) and 95% confidence interval (CI). Model 1, adjusted for sex, age (years), body mass index (kg/m2), family history of diabetes (yes or no); Model 2, further adjusted for current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), education level (≥9 years of education or not), systolic blood pressure (mmHg), fasting plasma glucose (mmol/L), total cholesterol (mmol/L), and triglycerides (mmol/L).

3.5. Predictive effect of the serum electrolytes clusters

The C statistic (95% CI) of the predictive models of conventional risk factors (age, sex, family history of diabetes, BMI, and fasting plasma glucose) was 0.767 (0.746–0.788) for incident diabetes. The inclusion of serum electrolytes clusters to the diabetes‐predictive models slightly increased the C statistic, IDI, and NRI for predicting the risk of diabetes. The C statistic, ΔC statistic, IDI, and NRI was 0.769 (0.749–0.790), 0.002 (0–0.005), 0.002 (0–0.003), and 0.13 (0.076–0.21), respectively.

4. DISCUSSION

In this large longitudinal study of 4937 community‐dwelling Chinese adults without baseline diabetes, we identified three clusters based on seven commonly measured serum electrolytes. The three clusters performed well in differentiating the risk of developing diabetes and different cardiometabolic trait progression. Cluster A was characterized as elder age, more women, with a higher level of serum chlorine, favorable β‐cell function, and lower TG and showed a moderate and stable BMI and increased serum HDL‐C over the follow‐up periods. Cluster B had a higher baseline serum iron level and multiple metabolic disorders and showed a persistent higher BMI and unfavorable β‐cell function and accelerated deterioration in glucose metabolism and progression of insulin resistance. Cluster C had a higher baseline level of serum phosphorus, younger age, and lower BMI but also an unfavorable lipids profile and the most sharply increased serum LDL‐C. As compared to Cluster A, Clusters B and C were associated with a higher risk of diabetes. Cluster A could be considered as “normal” or low risk for diabetes. Cluster B could be considered as a high risk of diabetes with significant deterioration in glucose metabolism. Cluster C was comparable with A, except for the more deleterious lipids metabolism, which indicated a moderate risk of diabetes.

Individuals in Cluster A were the oldest ones but had the lowest or delayed risk of developing diabetes, which might be because of the higher level of baseline serum chlorine, higher level of baseline β‐cell function, and lower level of baseline TG. Individuals in Cluster B had a higher risk of developing diabetes than those in Cluster A, which might be because of the higher level of baseline serum iron and systemic multimetabolic disorders. Individuals in Cluster B had unfavorable β‐cell function, higher levels of BMI, fat mass, TC, LDL‐C, and liver enzymes at baseline. Over an average follow‐up of 4.4 years, individuals in Cluster B still had higher BMI and unfavorable β‐cell function, together with accelerated deterioration in glucose metabolism and progression of insulin resistance. These features indicated individuals in Cluster B had systemic multimetabolic disorders. Higher level of baseline serum iron and systemic multimetabolic disorders may have jointly triggered and exacerbated the development of diabetes. Individuals in Cluster C were the younger ones, had lower level of BMI, but still had a higher risk of developing diabetes than those in Cluster A, which might be because of the higher level of baseline triglycerides, fat mass, and TC and most sharply increased level of serum LDL‐C during follow‐up.

Classified individuals at risk for diabetes and complications would aid in detecting diabetes pathophysiological subphenotypes and predicting future metabolic trajectories. 26 Adopting indicators link to diabetes pathogenesis, accurate indicators of insulin secretion and insulin sensitivity, individuals at elevated risk for type 2 diabetes were classified into six distinct pathophysiologic subphenotypes titled (1) low risk, (2) very low risk, (3) β‐cell failure, (4) low risk obese, (5) high risk insulin resistant fatty liver, and (6) high risk visceral fat nephropathy. 13 Of these, subphenotype 4 was characterized by obesity but low glycemic deterioration; subphenotype 5 was characterized by obesity, insulin resistance, high level of fatty liver, and elevated risk of type 2 diabetes, vascular disease, renal disease, and mortality; and subphenotype 6 was characterized by high amounts of visceral fat and elevated risk of microalbuminuria and chronic kidney disease. Our study used the clustering of seven common serum electrolytes to replicate the classification of nondiabetes. We found three distinct clusters and analyzed their diabetes risk and metabolic profile, including body composition, blood pressure, glucose and insulin levels, insulin resistance and insulin secretion, lipids profile, and liver and kidney function. We found Cluster B (systemic multimetabolic disorders with elevated risk for diabetes) in our study similar to subphenotype 5 in Tübingen Lifestyle Program (TUEF/TULIP) cohort, 13 but Cluster A (old age but with low risk of diabetes) and Cluster C (young age, lower level of BMI but with elevated risk for diabetes) were significantly different. These results suggested that introducing additional traits to stratify individuals susceptible to diabetes is feasible to disentangle pathophysiologic subphenotypes and implement efficient prevention strategies.

The distinct metabolic profiles and diabetes risk between clusters were validated by the association of the dominant serum electrolytes with risk of diabetes. Mechanically, excessive iron could promote β cell damage and apoptosis, impair insulin signaling, diminish insulin induced glucose transport, and result in deleterious glucose homeostasis. 27 Magnesium deficiency could inhibit β‐cells proliferation and mass, reduce β‐cells activity, increase insulin resistance, and decrease insulin secretion. 16 , 28 , 29 In turn, serum insulin would decrease serum magnesium level by promoting excretion in renal, resulting in a vicious cycle. 30 Potassium deficiency could decrease insulin secretion and increase ratio of proinsulin to insulin secretion. 31 Excessive calcium could inhibit insulin exocytosis. 32 , 33 Low serum sodium would active sympathetic nervous system and renin‐angiotensin‐aldosterone system, which would reduce insulin sensitivity, promote compensatory insulin secretion, and, in turn, induce insulin resistance and diabetes. 34 These factors deleterious glucose homeostasis and exacerbate type 2 diabetes and related complications.

To the best of our knowledge, it is the first investigation reporting the stratification of risk of developing type 2 diabetes and progression in glucose and lipid metabolic traits based on multiple common serum electrolytes. Multivariable defined clusters performed well in differentiating individuals to different classification for diabetes risk. Besides, our study included comprehensive metabolic indicators to show the distinct characteristics of each cluster. Second, the relatively large sample size, well‐defined community setting, and the highly homogeneous population were a great foundation for our analysis. We also considered a comparable full list of covariates in the analysis, which allowed us to control for the confounding factors between the clusters and risk of incident diabetes to the greatest extent. Several limitations should be acknowledged. First, the serum electrolytes level was measured at baseline by using one blood sampling. It forbids us to assess the association between the dynamic changes in serum electrolytes and diabetes risk. Multiple follow‐up measurements of serum electrolytes are needed to support our findings. In addition, according to the 2021 American Diabetes Association criteria, in the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples. The diagnosis of diabetes in our study was based on a single measurement of fasting and 2 h‐OGTT plasma glucose, which may result in an overestimate of diabetes incidence, and need to be cautious when generalizing the results to clinical practice. Second, serum electrolyte levels could change when an abnormality occurs. For example, individuals at high risk of diabetes might increase urinary electrolytes loss, which may lead to potential reverse causation. However, our study was based on a follow‐up prospective design to assess the baseline serum electrolyte with risk of future diabetes. We excluded individuals with known diabetes or cardiovascular diseases at baseline, the status of the diseases that might influence serum electrolyte levels. Third, we used elbow method in the selection of the optimal number of clusters. Whether the approach was inferior to conventional predictions from multivariable modeling need further warranted, 6 but cluster analysis shows superiority when exploring the association of various elements with a certain disease, which can aggregate and classify similar characteristics to identify the group with high risk. 35 Fourth, this classification was derived primarily from middle‐aged and elderly adults in Chinese, which minimizes the confounding effects by ethnic background but generalizing this conclusion to the youngers or other ethnicity population need to be cautious.

In conclusion, our study took seven common serum electrolytes simultaneously into account to stratify nondiabetes and found three distinct clusters differing in diabetes risk and progression of glucose and lipid metabolic traits. The investigation provides a powerful, convenient, and easily available method of risk stratification for nondiabetes. These analysis strategy aid in identifying more individuals susceptible to diabetes and benefit for early prevention and reducing the risk of long‐term diabetes and cardiovascular disease.

DISCLOSURE

The authors declare that they have no conflict of interest in this work.

CONTRIBUTION STATEMENT

Yanan Hou, Jiali Xiang, Yufang Bi, Zhiyun Zhao, and Min Xu conceived and designed the study. Yanan Hou, Jiali Xiang did the statistical analysis. Yanan Hou, and Min Xu drafted the manuscript. Zhiyun Zhao, Yufang Bi, and Min Xu supervised the study. Huajie Dai, Mian Li, Hong Lin, Shuangyuan Wang, Yu Xu, Jieli Lu, Yuhong Chen, Weiqing Wang, and Guang Ning contributed to acquisition, analysis, or interpretation of data. All authors revised the report and approved the final version before submission. Min Xu is guarantor of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

ACKNOWLEDGEMENTS

The investigators are grateful to all field workers for their participation and contribution. This work was funded by the National Natural Science Foundation of China (81941017, 81930021, 81970728, 91857205, and 82088102), the Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant Support Round 2 (20152508 and 2016307), and the Shanghai Shenkang Hospital Development Center (SHDC12019101, SHDC2020CR1001A, SHDC2020CR3069B). M. X., M. L., T.W., Y. X., J.L., Y. B., W. W., and G. N. are members of innovative research team of high‐level local universities in Shanghai.

Hou Y, Xiang J, Dai H, et al. New clusters of serum electrolytes aid in stratification of diabetes and metabolic risk. Journal of Diabetes. 2022;14(2):121-133. doi: 10.1111/1753-0407.13244

Yanan Hou and Jiali Xiang contributed equally to the work.

Funding information National Natural Science Foundation of China, Grant/Award Numbers: 81941017, 81930021, 81970728, 91857205, 82088102; Shanghai Municipal Education Commission‐Gaofeng Clinical Medicine Grant Support Round 2, Grant/Award Numbers: 20152508, 20161307; Shanghai Shenkang Hospital Development Center, Grant/Award Numbers: SHDC12019101, SHDC2020CR1001A, SHDC2020CR3069B

REFERENCES

  • 1. Federarion ID. IDF Diabetes Atlas. 9th ed. Brussels: Belgium; 2019. https://wwwdiabetesatlasorg [Google Scholar]
  • 2. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics‐2018 update: a report from the American Heart Association. Circulation. 2018;137:e67‐e492. [DOI] [PubMed] [Google Scholar]
  • 4. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990‐2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545‐1602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Bonnefond A, Froguel P. Clustering for a better prediction of type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:193‐194. [DOI] [PubMed] [Google Scholar]
  • 6. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data‐driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019;7:442‐451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult‐onset diabetes and their association with outcomes: a data‐driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361‐369. [DOI] [PubMed] [Google Scholar]
  • 8. Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes‐associated diseases in subgroups of patients with recent‐onset diabetes: a 5‐year follow‐up study. Lancet Diabetes Endocrinol. 2019;7:684‐694. [DOI] [PubMed] [Google Scholar]
  • 9. Zou X, Zhou X, Zhu Z, Ji L. Novel subgroups of patients with adult‐onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol. 2019;7:9‐11. [DOI] [PubMed] [Google Scholar]
  • 10. Wang W, Pei X, Zhang L, et al. Application of new international classification of adult‐onset diabetes in Chinese inpatients with diabetes mellitus. Diabetes Metab Res Rev. 2020;37:e3427. [DOI] [PubMed] [Google Scholar]
  • 11. Kahkoska AR, Geybels MS, Klein KR, et al. Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22:1537‐1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Hulman A, Simmons RK, Brunner EJ, et al. Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. Diabetologia. 2017;60:1252‐1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Wagner R, Heni M, Tabák AG, et al. Pathophysiology‐based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27:49‐57. [DOI] [PubMed] [Google Scholar]
  • 14. Eshak ES, Iso H, Maruyama K, Muraki I, Tamakoshi A. Associations between dietary intakes of iron, copper and zinc with risk of type 2 diabetes mellitus: a large population‐based prospective cohort study. Clin Nutr. 2018;37:667‐674. [DOI] [PubMed] [Google Scholar]
  • 15. Wang S, Hou X, Liu Y, et al. Serum electrolyte levels in relation to macrovascular complications in Chinese patients with diabetes mellitus. Cardiovasc Diabetol. 2013;12:146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hruby A, Meigs JB, O’Donnell CJ, Jacques PF, McKeown NM. Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle‐aged americans. Diabetes Care. 2014;37:419‐427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kieboom BCT, Ligthart S, Dehghan A, et al. Serum magnesium and the risk of prediabetes: a population‐based cohort study. Diabetologia. 2017;60:843‐853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Rooney MR, Pankow JS, Sibley SD, et al. Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Clin Nutr. 2016;104:1023‐1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Podmore C, Meidtner K, Schulze MB, et al. Association of multiple biomarkers of iron metabolism and type 2 diabetes: the EPIC‐InterAct Study. Diabetes Care. 2016;39:572‐581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Jorde R, Schirmer H, Njolstad I, et al. Serum calcium and the calcium‐sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromso study. Eur J Epidemiol. 2013;28:569‐578. [DOI] [PubMed] [Google Scholar]
  • 21. Huang Y, Bi Y, Xu M, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle‐aged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32:2321‐2326. [DOI] [PubMed] [Google Scholar]
  • 22. Lin L, Zhang J, Jiang L, et al. Transition of metabolic phenotypes and risk of subclinical atherosclerosis according to BMI: a prospective study. Diabetologia. 2020;63:1312‐1323. [DOI] [PubMed] [Google Scholar]
  • 23. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12‐country reliability and validity. Med Sci Sports Exerc. 2003;35:1381‐1395. [DOI] [PubMed] [Google Scholar]
  • 24. Fan M, Lyu J, He P. Chinese guidelines for data processing and analysis concerning the International Physical Activity Questionnaire. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35:961‐964. [PubMed] [Google Scholar]
  • 25. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ‐SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high‐risk state for diabetes development. Lancet. 2012;379:2279‐2290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Zhang C, Rawal S. Dietary iron intake, iron status, and gestational diabetes. Am J Clin Nutr. 2017;106:1672s‐1680s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Günther T. The biochemical function of Mg2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes Res. 2010;23:5‐18. [DOI] [PubMed] [Google Scholar]
  • 29. Gommers LM, Hoenderop JG, Bindels RJ, de JH B. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2016;65:3‐13. [DOI] [PubMed] [Google Scholar]
  • 30. Zhao B, Deng H, Li B, et al. Association of magnesium consumption with type 2 diabetes and glucose metabolism: a systematic review and pooled study with trial sequential analysis. Diabetes Metab Res Rev. 2020;36:e3243. [DOI] [PubMed] [Google Scholar]
  • 31. Meisinger C, Stöckl D, Rückert IM, et al. Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F4‐study. Diabetologia. 2013;56:484‐491. [DOI] [PubMed] [Google Scholar]
  • 32. Noordam R, Young WJ, Salman R, et al. Effects of calcium, magnesium, and potassium concentrations on ventricular repolarization in unselected individuals. J Am Coll Cardiol. 2019;73:3118‐3131. [DOI] [PubMed] [Google Scholar]
  • 33. Pittas AG, Lau J, Hu FB, Dawson‐Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta‐analysis. J Clin Endocrinol Metab. 2007;92:2017‐2029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Kong YW, Baqar S, Jerums G, Ekinci EI. Sodium and its role in cardiovascular disease ‐ the debate continues. Front Endocrinol (Lausanne). 2016;7:164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Guo W, Zhou Q, Jia Y, Xu J. Cluster and factor analysis of elements in serum and urine of diabetic patients with peripheral neuropathy and healthy people. Biol Trace Elem Res. 2020;194:48‐57. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Diabetes are provided here courtesy of Wiley

RESOURCES